LGL Group (NYSEAMERICAN:LGL) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

LGL Group (NYSEAMERICAN:LGL) posted its quarterly earnings data on Friday. The industrial products company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07), FiscalAI reports. The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.80 million. LGL Group had a net margin of 1.66% and a return on equity of 0.16%.

LGL Group Stock Down 1.6%

Shares of LGL traded down $0.12 during mid-day trading on Friday, hitting $7.43. The company had a trading volume of 6,750 shares, compared to its average volume of 13,059. LGL Group has a 1-year low of $5.45 and a 1-year high of $7.57. The business’s 50-day simple moving average is $6.95 and its 200-day simple moving average is $7.06. The stock has a market cap of $48.59 million, a PE ratio of 743.74 and a beta of 0.32.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. grew its position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,250 shares of the industrial products company’s stock after acquiring an additional 2,710 shares during the quarter. Osaic Holdings Inc. owned about 0.38% of LGL Group worth $154,000 at the end of the most recent quarter. 30.28% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of LGL Group to a “hold” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.